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Abstract 
This paper provides a brief review of the current literature on technology 
commercialization factors for heterogeneous medical devices. It intends to propose some 
technology commercialization factors focused on three novel medical devices. 
Technology commercialization factors provide a means for a company to prioritize which 
technologies to commercialize so that an organization’s resources are used most 
effectively. A survey was arranged in order to provide feedback for the proposed 
technology commercialization factors. The results of the survey are analyzed after getting 
feedback from a number of personnel involved in medical device industry. Based on the 
response of the participants, relative weightings of the proposed technology 
commercialization factors are calculated. Finally, the relative weightings are used to 
score the three novel medical device technologies. A brief statistical analysis of the 
proposed technology commercialization factors is also discussed here. 
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1 Introduction 
To foster innovation, it is essential for an organization to commercialize its technologies. 
Technology commercialization aims to transform technology innovation into products or 
services to create commercial benefits [1]. In other words, commercialization attempts to 
render market value by generating profit from innovations through incorporating new 
technologies into products or services. Many factors drive a firm’s decision to 
commercialize one new technology over another. Manufacturing companies must assess 
the likelihood of funding of the innovation from internal and external sources. Companies 
must estimate the profitability of the new venture, the ability to protect the intellectual 
property of the innovation, the size of the target market etc. [2].  
 
Technology commercialization includes various actions and components such as 
acquiring ideas with complementary knowledge, implementing the ideas, developing 
prototype, manufacturing saleable goods, and converting the goods into economic 
benefits by selling them [3]. Successful commercialization strategies are contingent on 
the technology's source, the availability of organizational resources and technological 
complexity [4]. 
 
For successful technology commercialization, it is crucial to document technological 
feasibility and market requirements in the initial investigation [5]. Effective 
commercialization depends on research on how the diverse sources of technology (e.g., 
university, research institute, industry) impact technology commercialization outcome 
[6]. With more applied research there’s a chance of higher marketability of the 
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innovation, which leads to higher rates of technology commercialization [7].  Therefore, 
extent and quality of research concerned with the technology fortifies the dimension of 
feasibility of that innovation.  
 
Strategic technology transfer plays a vital role in technology commercialization. Eldred 
and McGrath [8] suggested that technology transfer is a very important concept while 
linking the technology development process and product development process. Duhm 
and Wielockx [9] stated that successful technology commercialization depends on a 
gradual technology development process. Design development process also depends on 
the universities which developed the technologies at universities [10] [11]. Protecting the 
patent of a new technology is also essential to commercialize it. To prevent imitation of 
extremely innovative technologies, the startups can follow the pathway of patenting and 
commercializing it [12]. Extremely innovative technologies can attain commercial 
success when the inventor of the technology contributes to the further development of the 
technology [13]. In that case, addition of new aspects to the existing technology would be 
more facilitated. 
 
A firm’s decision-making for a technology innovation is greatly influenced by weighting 
the technology commercialization factors. A firm shouldn’t follow all potential 
technologies, because not all technologies would render the desired market values and the 
firm has limited resources. A company must estimate all possible variables, which would 
affect an innovation’s relative advantage over other technologies of that company [14]. 
All possible consequences for each technology must be assessed to get a comparative 
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picture of feasibility and possible added-values. A systematic way of choosing which 
technology to commercialize will lead to the ultimate economic success for a company. 
That’s why weighting the commercialization factors are critical for an effective pathway 
from a business perspective.  
 
Based on literature review on technology commercialization and medical device 
innovation, this article intends to identify some technology commercialization factors 
(TCF) of heterogeneous medical devices. A survey via Qualtrics.com is conducted to 
provide feedback on the proposed TCFs. The feedback is then used to assign relative 
weights to the proposed TCFs. The results of this effort have been applied to three 
proposed medical devices: high pressure water jet craniotome, peripheral lung biopsy and 
glioblastoma tumorID. The main contribution of this paper is to provide a weighted 
scoring of several technology commercialization factors for these devices after 
performing a SWOT analysis. A novel decision matrix is proposed from the SWOT 
analysis. The prospect of successful commercialization is represented from the reflection 
of the overall score of the medical device technologies.  
 
The rest of this article is structured as follows. Section 2 presents literature background of 
technology commercialization factors and their weightings for medical device 
technologies. Section 3 depicts the research methodology of this study. Section 4 
discusses the proposed technology commercialization factors (TCF). Section 5 introduces 
an overview of three medical device technologies and a decision matrix of these 
technologies based on the proposed TCFs of Section 4. Section 6 presents the survey 
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methodology. The survey was conducted to provide relative weightings to the proposed 
technology commercialization factors. Section 7 includes discussion of the results of the 
survey and an implementation of the results on the mentioned medical device 
technologies. Finally, section 8 concludes the entire study.  
 
2 Literature Review 
 Technology Commercialization Factors and their weightings for medical 2.1
devices 
The literature review of this study includes discussion of technology commercialization 
(TC) factors and their weightings. Many prior studies have paid attentions to decision 
criteria for successful technology commercialization. An overview of these factors 
summarized in a study by Kirchberger [6] is reproduced in Table 1: 
 
Table 1: List of Coded TC factors [6] 
Final Factors Initial factors 
Potential Market size Potential market growth rate, adoption of technology 
Property rights Licensing, patent availability, patent scope, reimbursement 
requirements, fairness of property rights distribution 
Technology suitability for 
commercialization  
Feasibility, age of innovation, competition in target market 
segment, development stage of technology, expected time 
to market, innovation scope, projected market share, 
pioneering nature 
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Final Factors Initial factors 
Technology application 
value 
Customer satisfaction, product development time, 
technology Customer satisfaction, product development 
time, technology assessment, technology carve-outs, 
technology complexity, technology importance. 
Technology transfer 
strategy 
Experimenting with technology in value networks, choice 
of strategy, innovation strategy, overcoming bottlenecks, 
project management of the transfer 
University policy and 
structure 
Autonomy of technology transfer office, degree of support, 
entrepreneurial orientation, design of process, quality of 
research, number of researchers, university size, 
organizational ambidexterity, type of university, previous 
spin outs 
Resource availability Access to finance, access to incubators, funding at 
university, internal human and technology-based 
manufacturing sources, availability of venture capital 
Researchers’ individual 
characteristics 
Commercialization capability, faculty quality, marketing 
skills, motivation, risk taking aptitude, nationality, star 
scientists, time allocation, willingness to engage in transfer.  
 
The decision criteria for technology commercialization centers around early stage 
impediments, which would influence the process of transforming a technology to market. 
Patent scope, target market research, technology transfer from startups, potential 
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resources, etc., are important deciding factors for commercializing a new technology. 
 
Kim et al. [15] demonstrated two technology commercialization capability-related 
factors: the manufacturing function (MFF) and the marketing function (MKF). Kim et al. 
[15] also introduced the learning function (LF) and the external networking function 
(ENF), both functions measure the R&D (Research and Development) capability of a 
company. Here, R&D capability is related to a dynamic capability to implement acquired 
knowledge of research and development on technology innovation performance. MFF 
relates to continuous improvement of manufacturing system. MKF refers to marketing 
ability and knowledge about the target market.  
 
The learning function (LF), mainly monitoring trends of R&D, proved to have a 
significant positive influence on both technology commercialization capability factors.  
Additionally, the external networking function (ENF) had a significant positive influence 
on the manufacturing function (MFF). Here, ENF relates to new market entry through 
external technology cooperation. Both of the technology commercialization capability-
related factors, the manufacturing function (MFF) and the marketing function (MKF) had 
a significant positive influence on innovation performance [15]. 
 
Mehta [16] presented a linear roadmap of commercialization plan for a biomedical 
invention including its components. Their proposed plan outlines several important 
technology commercialization factors. The roadmap is portrayed below [16]:
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Plan Position Patent Product Pass! Production Profits 
Industry context Market research Intellectual 
property rights 
New product 
development 
(NPD) 
Regulatory 
plan 
Manufacture Reimbursement 
Technology 
positioning 
and 
strategy, 
industrial 
value chain 
context 
Market need, 
market size, 
profitability 
Intellectual 
property 
and 
licensing 
strategy, 
Business 
models 
Stage-gate new 
product testing 
and development 
plan, budget 
Regulatory 
Strategy- 
working with 
FDA towards 
approval 
Production 
planning 
Coverage, 
Coding, 
Payment, 
Distribution, 
Marketing and sales 
planning 
Figure 1: Components of a commercialization plan and roadmap 
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This roadmap emphasizes various stages required to commercialize an innovation 
marketed in a competitive and regulated marketplace. This roadmap supports the 
conclusion that the biomedical technology commercialization process depends on the 
factors such as market research, licensing strategy, intellectual property search, 
regulatory and reimbursement plans etc.  
 
To introduce a scoring methodology of innovation capacity, a set of guidelines on [17] 
incorporating results of an online survey with a goal to better understand the values 
regrading innovation has referenced.  The study suggested that the challenges and 
opportunities can be identified and prioritized through a thorough interpretation of survey 
results, which would lead to focused corrective action [17].  
 
A weighting of some critical factors for technology commercialization process was 
developed by M. Jung et at. [18]. Their weighting was based on relative variable 
importance (RVI) using the classification tree (CT) method. RVI is the relative order of 
priority among the factors considering the interaction between input factors [18]. In this 
CT, the most influential factor was assigned as marketing capability, RVI value of 1. The 
following Table 2 is reproduced from the study of TC factors by CT process [18]. 
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Table 2: Technology commercialization Critical Factors with RVI dimensions by CT 
(classification tree) process [18]  
Critical factors RVI Dimension 
Marketing capability 1.0000 
Cooperation with developer 0.7217 
Effort for technical improvement 0.5633 
Willingness and capability of adopter 0.5376 
Supply of complementary technology 0.5334 
Financial capability 0.5288 
Market condition 0.5077 
Excellence of technology 0.2420 
Technical capability of adopter 0.2341 
 
S. Kumar et al., [19] used the Analytical Hierarchy Process (AHP) to weight the critical 
technology transfer and commercialization factors. The result of the AHP methodology 
was utilized to evaluate critical factors of effective technology transfer process in India. 
A summary of their results [19] are shown in the following table: 
 
Table 3: Summary of results showing weight of Critical Factors of technology transfer 
(TT) by AHP [19] 
Dimensions of Critical factors of TT Weight of dimensions 
Regulatory concerns  0.48159 
Relative advantage in economic terms 0.19505 
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Dimensions of Critical factors of TT Weight of dimensions 
Technical features 0.14384 
Marketing related benefits and forces 0.10065 
Managerial and strategic issues 0.07886 
 
Here, ‘Regulatory concerns’ indicates the significance of legal and regulatory barriers at 
the national and international levels. ‘Relative advantage in economic terms’ relates to 
cost effectiveness, profitability etc. ‘Technical features’ includes technological abilities 
of suppliers, local suitability of technology, compatibility etc. ‘Marketing related benefits 
and forces’ refers to entry to new market, market requirements etc. Finally, ‘Managerial 
and strategic issues’ indicates strategic implications, resources etc. [19].  
 
The literature review from the above studies summarizes previous efforts to identify 
technology commercialization (TC) factors and efforts to weight them. Inquiries into the 
relative weighting of technology commercialization factors, for medical device 
innovations in particular, have been especially rare. This study aims to identify several 
TC factors for medical device innovations. The proposed factors for the current study are 
discussed in the Section 4.  
 
3 Research Methodology 
The research methodology of this study includes proposing technology 
commercialization factors for medical device innovations, a SWOT analysis and a 
decision matrix for the proposed medical devices, a survey to weight the proposed TCFs 
11 
and apply the weighted TCFs to get overall score for the proposed medical devices. A 
flowchart of these activities is shown below: 
 
Figure 2: Flow chart for the research methodology of the study 
 
SWOT analysis and decision matrix were discussed in Section 5.4 and 5.5. The analysis 
and implementation of the decision matrix will be discussed in Section 7.1.  
The next chapter describes the proposed TCFs, how these proposed TCFs were chosen, 
and importance of these TCFs for successful commercialization. 
 
4 Proposed Technology Commercialization Factors 
Successful technology commercialization is imperative for survival in the competitive 
markets [20].  An organization cannot commercialize all potential technologies due to 
limited resources. The organization must decide which technology would exhibit most 
potential positive aspects in terms of economic success. Therefore, factors affecting 
decision criteria for technology commercialization hold immense interest.  
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Commercialization of medical devices is part of medical device design and development 
activities. This study focuses to identify deciding factors for commercializing medical 
devices in particular. To know these deciding factors, activities for commercializing new 
medical devices need to be addressed. Steps of medical device design for innovation of 
medical devices are provided below [21]: 
 
Table 4: Steps of medical device design for commercialization [21] 
Phases Stages Activities 
Identify Need Finding Strategic focus 
Need statement 
Need Screening Market analysis 
Stakeholder analysis 
Invent Concept generation 
 
Ideation 
Initial concept selection 
Concept screening 
 
Intellectual Property basics 
Regulatory basics 
Reimbursement basics 
Business models 
Concept exploration and testing 
Final concept selection 
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Phases Stages Activities 
Implement 
 
Strategy development 
 
IP strategy 
R&D strategy 
Clinical strategy 
Regulatory strategy 
Quality management  
Reimbursement strategy 
Marketing and stakeholder strategy 
Sales and distribution strategy 
Competitive advantage and business strategy 
Business planning 
 
Operating plan and financial aid 
Strategy integration and communication 
Funding approaches 
Alternate pathways 
 
At this point, several activities in the medical device innovation process require concepts 
from the previous discussion on technology commercialization factors. After reviewing 
the above literature background this paper identifies a number of deciding factors which 
lead to successful commercialization.  
 
From the literature overview, a summary of some major factors that are significant for 
successful technology commercialization are: technology transfer strategy/ property 
rights [6], feasibility [6] [16], resource availability [6] [18], manufacturing and marketing 
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functions [15], market entry strategy [15] [18], market size [6] [21], technology 
positioning [16], licensing strategy [6] [16], regulatory strategy [16] [19] [21], 
reimbursement strategy [16] [18] [21], effort for technical improvement [18], technical 
capability [19], regulatory concerns [19], market research [16] [21]. After combining all 
of these factors, this study intends to generalize them and propose a novel list of 
technology commercialization (TC) factors, especially in the context of medical device 
technology innovation. 
Hence, in light of literature review along with study of medical device innovation 
activities, the following six TC factors are proposed after summarizing the major TC 
factors. Following is a table showing how these six TC factors were proposed after 
summarizing the major TC factors from literature background. The corresponding 
references of literature, where these TCFs were mentioned, are also mentioned here. 
 
Table 5: Proposed TCFs based on literature review  
Major TC factors from literature 
background 
Proposed TCFs: summarizing the 
major TCFs from literature reviews 
Market research [16] [21], market entry 
strategy [15] [18], market size [6] [21], 
marketing functions [15] 
Market size 
Effort for technical improvement [18], 
feasibility [6] [16], technical capability [19], 
technology positioning [16] 
Technology feasibility 
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Major TC factors from literature 
background 
Proposed TCFs: summarizing the 
major TCFs from literature reviews 
Regulatory concerns [19], regulatory strategy 
[16] [19] [21] 
Regulatory pathway  
Reimbursement strategy/potential [16] [18] 
[21] 
Reimbursement potential 
Transfer strategy/ property rights [6], 
licensing strategy [6] [16] 
Technology transferability/ Licensing  
Resource availability [6], financial capability 
[18] 
Resource availability  
 
The discussion for each proposed TC factor is presented below. 
 
 Market size 4.1
Market analysis along with projection of the segment market is one of the most important 
initial steps for commercializing a new technology. A strategic and systematic market 
plan plays a vital role in technology commercialization, with an emphasis on profiling 
and finalizing the target market. Market orientation and understanding the customers are 
the key factors for successful commercialization [6].  Innovators should perform an 
efficient market analysis, which includes market prediction along with the identification 
of end users [22]. They also need to estimate the target market size as well.  
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Per Slater and Mohr (2006) [23], the ability to identify appropriate target markets also 
supports the successful commercialization of technologies. Per M. Eyring et al. [24], 
early identification of emerging markets by detecting the unmet needs helps the startup to 
grow profits. Strategic market analysis may also identify a low-end solution or a 
disruptive innovation. This analysis will be based on the target market landscape 
followed by a need statement in the initial stage of commercialization. The market 
landscape may include competitive dynamics of segment market and opportunities of 
potential expansion of market [21].  
 
A well-planned market analysis will reflect needs from the customers’ perspective, which 
would lead to an effective estimate of projected market size. Hence, market size analysis 
is a significant contribution to the development of commercialization. 
 
 Technology Feasibility 4.2
The factor of technology feasibility relates to the features of the technology which 
support or hinder its commercialization [6]. This introduces the idea of how much 
invention necessary for market introduction of the technology. In other words, 
technology feasibility is the likelihood of economic success with improvement of existing 
technology. Prototyping is helpful to identify how much invention will be needed in later 
stages in marketing. The driving factors that stipulate technology feasibility are, the 
quality of the technology, scope, pioneering nature (type of innovation), and expected 
time to market growth. Analysis of technology feasibility can help lead research toward 
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the scope of cost reductions of the technology innovation [25]. A strategic feasibility 
study will prevent problems later in design verification and validation activities of the 
commercialization process [26]. 
 
Technology feasibility can also be reflected by technology readiness level (TRL). TRL is 
related to technology capabilities. When upgrading from technology development to 
product development, the risk is higher for a lower-TRL technology [27]. To reduce risks 
for medical technologies in order to increase the scope of feasibility certain steps are 
essential such as, initial market analysis, hypothesis test of prototype, design review, 
Premarket Notification or 510(k) (for class II device) or Pre-Market Approval (for class 
III device) [27]. 
 
 Technology transferability/ Licensing  4.3
Technology transferability mainly focuses on strategies for early stage impediments in 
commercialization. Research through universities helps foster technology-based 
economic growth nationwide. The diffusion of university-developed intellectual property 
(IP) is therefore a vital and dynamic process.  To protect the patents of these research 
work, proper licensing activities are essential. Research conversion to IP leads to 
academic start-ups or external entrepreneurial companies. Most major U.S. research 
universities have set up technology transfer office (TTO) to patent the IP and manage the 
development and commercialization of their innovations [28]. 
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The TTOs use a metrics-based index that assess the relative position among peers and in 
distinguishing best practices. From a study of 2012 to 2015 [28], the index is measured as 
four indicators of technology transfer success: how many patents issued, how many 
licenses issued, amount of licensing income, and number of start-ups formed. This data 
was collected by the Association of University Technology Managers (AUTM) through 
the AUTM’s Annual Licensing Activity Survey [28]. Another study by Galbraith et al. 
(1991) [29] suggested that successful technology transfer is subject to the incorporation 
of the requirements of the end users of the technology when choosing the R&D projects.  
 
Gans and Stern [30] claimed that startups would have a higher chance of successful 
product development if they have strong intellectual property. With appropriate 
patenting/licensing, they can collaborate with other cooperative firms to commercialize 
their technologies [30]. Companies intending to commercialize a new product, should 
pursue to secure their freedom to operate (FTO), which is to ensure that the 
manufacturing, marketing and use of their new product or service does not infringe the IP 
rights of others [21].  
 
Developing a medical device with FTO and IP protection is a significant route to 
technology transfer. In order to assure FTO, an extensive patent search is required. A 
patent is a legal document that gives an inventor the right to prevent others from 
commercial use of that invention. Criteria for obtaining a patent are utility, novelty and 
obviousness. Strong IP can be a source of potential revenue through licensing agreement. 
Strong IP is also a barrier for market entry for other competitors [21].  
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Some factors that lead to a high rating for technology transferability are good patent 
coverage, business friendly IP policies at universities and support of the inventors when 
transferring from university. Protecting inventions by licensing with a strategic IP 
landscape has a big positive impact on technology commercialization.  
 
 Regulatory pathway 4.4
Developing an effective, strategic approach to regulation is of critical importance in the 
medical device development process. Regulatory approval or clearance must be approved 
by the FDA. The manufacturer must learn about the medical device classification system. 
The definition of medical device quoted from FDA [31] is stated below: 
“A machine, implement, implant, in vitro reagent, apparatus, instrument, or other similar 
article, including any component part which is: 
1. envisioned for the diagnosis of disease or other conditions, or to lessen or treat, or 
prevent disease, in man or other animals, or 
2. intended to impact any function of the body of man or other animals, and which 
does not attain any of its primary intended purposes through chemical action on 
the body of man or other animals and which is not reliant on being metabolized 
for establishing its primary intended purposes” [31].  
 
Following are the detailed regulatory activities required to commercialize a medical 
device innovation. 
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4.4.1 Device classification  
Once a new product is considered as a medical device, the innovator determines its risk 
profile in accordance with the FDA safety classification system. Following is a brief 
discussion of each class of medical device and the regulatory pathway for each class of 
medical device [21]: 
 
Class I medical devices are typically simple in design. There is no need for clinical trials 
or proof of safety or efficacy. Examples of Class I medical devices are bandages, 
bedpans, examination gloves, hand-held surgical instruments, etc.  
 
Class II medical devices are often non-invasive, but more complicated in design than 
class I devices. Examples of Class II medical devices are X-ray machines, powered 
wheelchairs, surgical needles, infusion pumps, and suture materials. 
 
Class III medical devices are high-risk devices. Typically, they are implantable, 
therapeutic, or life-sustaining devices. Examples of Class III medical devices are 
replacement heart valves, implantable pacemakers, and implanted cerebellar simulators. 
 
Regulatory pathway for class I device must follow the ‘general controls’: registration of 
the establishment with the FDA, medical device listing, general FDA labeling 
requirement, compliance with quality system regulation (QSR). Most of the Class I 
devices are exempt from premarket clearance. Class II devices must meet all class I 
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requirements, in addition to ‘special controls’ including: special labeling requirements, 
mandatory performance standards, design controls, and post market surveillance. Class II 
devices are generally cleared to market via the 510(k) processes.  Class III devices must 
meet Class I and Class II requirements, in addition to stringent regulatory approval 
requirements that necessitate valid scientific evidence to demonstrate their safety and 
effectiveness. Class III devices are generally approved by the PMA regulatory pathway 
[21]. 
 
4.4.2 510(k) Approval and Substantial Equivalence to the new device 
The three medical device concepts to be analyzed in this study are class II devices (see 
section 5). So, 510 (k) approval from FDA is compulsory for marketing and commercial 
distribution. 
 
It is mandatory that applicants compare their intended 510(k) device to one or more 
similar existing devices currently in the US market. The device cannot be 
commercialized until FDA approves a 510(k)-clearance stating that the device has been 
determined to be substantially equivalent (SE) [32].  
 
A device is substantially equivalent (SE) if it verifies the same technological 
characteristics and the same intended use as a legally marketed device, which is known as 
the predicate. A device that was legally marketed prior to May 28, 1976 is a legally 
marketed device (or pre-amendments device). Once the submitter gets SE clearance, the 
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device can start the marketing process. The SE determination usually takes 90 days and is 
made based on the information by the submitter [33]. 
 
Per the FDA, “applicants must compare their device to one or more similar legally 
marketed devices to support their SE claims. If the device is SE to a predicate, it is placed 
in the same class. If it is not SE, it becomes non-SE and is placed into Class III” [34]. 
Only one predicate device is required, when manufacturers would consider comparing 
substantial equivalence. Identifying a single predicate device to simplify and facilitate the 
decision-making process is encouraged by the FDA [35]. Pre-clinical data is necessary to 
validate that the new device performs equivalent to the predicate. This will prove that the 
device’s safety is equivalent to that of the predicate. Thus, technological characteristics of 
the new device are authenticated. 
 
There might be some situations where the new device has the same intended use as an 
existing marketed device, but the new device’s technological characteristics resemble a 
second marketed device, which has a different intended use. In this case, manufacturers 
will attempt to adopt the 510-k pathway with a split predicate for the new device to 
demonstrate substantial equivalence [32]. The split predicate will account for one existing 
marketed device for the same intended use and another device for same technological 
aspects.  
 
The above discussion on regulatory pathway depicts the detailed regulatory activities and 
hurdles to commercialize a Class II medical device. The extent of regulatory hurdles, 
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which mostly depends on the device classification, must be considered by the innovator 
to commercialize the device. For example, Class III devices are high-risk devices, which 
would require the most stringent regulatory approval. 
 
 Reimbursement Potential 4.5
After receiving approval to market, next stage of the product success depends on good 
reimbursement potential, which relates to the market adoption of the medical device 
within medical community, market growth and sales growth [36]. Reimbursement for 
medical devices is handled by both public and private insurance programs. Innovators 
will achieve reimbursement faster and more easily if they can utilize existing 
reimbursement pathways (existing CPT code) for a new technology, rather than pursuing 
new coding [21].  
 
Coverage, coding and payment are the three most important concepts for reimbursement 
of a product [36]. These three concepts are briefly discussed below:  
 
4.5.1 Coverage 
Coverage refers to the terms and conditions for payment. Coverage will be applicable for 
new medical procedures and technologies that are not presently defined in the regulatory 
system [36]. It is also possible that the devices will be covered under existing codes.  
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4.5.2 Coding 
Innovators will achieve reimbursement faster and more easily if they can use existing 
coding for the invention rather than pursuing a new code [21]. CPT (Current Procedural 
Terminology) codes are used to define the evaluations and any other medical procedure 
performed by a healthcare provider on a patient. [37]. CPT codes indicate for what 
procedures the healthcare provider would be reimbursed from the insurance payer. The 
coding landscape is different for inpatient and outpatient medical procedures. Coding also 
differs depending on whether the medical procedure is performed by physician or 
technician [36]. Hence, a manufacturer must assess the potential coding scenario of the 
new invention before commercializing it.  
 
4.5.3 Payment 
Payment is the remuneration by health insurance plans or government-funded programs, 
such as CMS (Centers for Medicare & Medicaid Services). In other word, payment 
describes who is paid, and how much. Medicare payment to hospitals is made under 
separate payment systems: inpatient and outpatient settings. Inpatient is the case of 
hospital stay of more than 24 hour and outpatient is the setting where patients are 
discharged from hospital on the same day [33]. 
 
Accomplishing a strong reimbursement landscape is quite challenging for a startup 
company. The startup or innovator has to ensure that they are adequately paid for 
providing the technology to end customers. Startups have to prove the economic value of 
their offerings as well as their clinical benefits [21]. Strong reimbursement strategies with 
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knowledge of appropriate and strategic coding landscape will then have a positive impact 
on commercialization.  
 
 Resource Availability 4.6
Per Boardman and Ponomariov [38], resource availability relates to the extent of 
resources for the commercialization of the product. The resources include venture capital, 
suitable consultant or professional personnel, sources of funding, supporting structure, 
etc. And availability of these resources impacts the technology commercialization 
process from the initial to final stages.  Although funding from industry grants might 
positively influence the interaction between university and industry, it does not 
necessarily increase the prospect of university researchers to initiate a company.  
 
The organizational resources and innovative capabilities are important driving forces for 
new ventures to achieve successful commercialization [39]. Organizational resource is 
the entity in which the new venture possesses human, tangible, and intangible resources. 
A well-trained labor force with proper manufacturing knowledge act as an effective 
catalyst for strong prospect of technology commercialization. Research and marketing for 
new venture requires adequate financial sources to aid successful commercialization. 
Strong intellectual property landscape and innovative manufacturing schemes can act as 
intangible resources, which facilitate new product development and help to maintain a 
competitive edge in the market [39].  
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In addition, the combination of proper and skilled resources helps accelerate a TC 
process. Human or technological resources with manufacturing skills enhance the 
company’s knowledge on advancing commercialization [40]. Here, human resources 
comprise the expertise and skills of manufacturing personnel of an organization. Unique 
skills of human resources can offer competitive advantage for a firm. A well-organized 
and skillful labor force can lead to an innovative environment for an organization. 
Knowledge of new employees opens a new window of expedited innovative activities, 
which ultimately triggers speedy technology commercialization. Modern manufacturing 
technologies facilitate a firm’s flexibility to increase its variety of the products, where 
multiple products can be manufactured at lower cost than a single product. This 
incremental and innovative product development with appropriate manufacturing skills 
help to achieve successful technology commercialization of new products [40]. 
Furthermore, skilled manufacturing personnel help eliminate wastes throughout the 
product development cycle and enhance the firm’s manufacturing capability by adjusting 
the new product specifications. This ultimately helps expedite the technology 
commercialization process. 
 
Following are the discussions of the proposed medical device innovations, to which 
relative weighting of the mentioned technology commercialization factors will be 
applied. 
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5 Concepts to be Weighted: Overview of three projects of medical device 
 High pressure water jet Craniotome 5.1
The high-pressure water jet Craniotome intends to reduce the incidents of dural tear 
during craniotomy by attaching a fluid discharge nozzle to a dura guard which discharges 
a high pressure sterile saline solution. The invention includes an elongate leg, a guard, 
and a fluid discharge channel with a port connected to a craniotome [41] [42]. 
This device introduces a way to reduce the incidence of dural tear in craniotomies by at 
least half while not increasing the time it takes to remove the bone flap, as compared to 
current methods. In approximately 20-30% of craniotomy procedures, there’s an 
occurrence of dural tears. Dural tears increase the risk of a cerebrospinal fluid leak after 
the craniotomy procedure and increase the procedure time [42]. 
 
The proposed tool is a modification of the existing craniotomes. It acts like a dura guard 
protecting dura from the cranium. It intends to facilitate separation of dura from cranium 
ahead of the craniotome. Water separation by waterjet dissection has been demonstrated 
in the literature [43]. 
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Figure 3: Proposed High pressure water jet Craniotome 
 
F. Barker et al. conducted a study [44] of statistics of brain tumor procedures between 
1988 and 2000. In this timeframe, craniotomies were performed at 98% of the 955 
hospitals in the study. It was also found that the 100 highest-caseload U.S. hospitals 
performed about 41% of the total U.S. surgical primary brain tumor caseload in 2000 
[44].  
The global neurology devices market size was valued at USD 6.2 billion in 2014 [45]. 
The global market for powered surgical instruments in 2014 is estimated to be around 
$1.5 to 1.6 billion [46]. During the forecast period of 2014 to 2019 this market is 
estimated to grow at a moderate CAGR (compound annual growth rate). A CAGR of 
9.42% is estimated as a forecast for the global neurosurgery market to grow during the 
period of 2016 and 2020 [46]. The estimate was delivered after inputs from industry 
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experts and in-depth market analysis.  Key vendors to operate this market are DePuy 
Synthes, Integra LifeSciences, Medtronic, Stryker, Abbott Laboratories etc. [47].  
According to research by Grand View Research, Inc. the global neurology device market 
is expected to reach USD 10.8 billion by 2022 [48]. Approximately 160,000 craniotomies 
performed per year in the United States [41]. A Craniotomy drill set costs about $(900-
1500) [62].  
 
There are a few challenges for the high-pressure water jet craniotome. Patient outcomes 
may not change significantly. Target market may be small for this device and more 
research is desired. There is large number of established competitors for this device. 
 
Opportunities for this proposed device include a clear need from neurosurgeons, 
possibility of application of this device in other neurological procedures (e.g. laser), and a 
large number of potential licensing partners. [41]. 
 
 Peripheral lung biopsy 5.2
Lung cancer is one of the leading causes of cancer deaths worldwide [49]. Tasneem 
Lokhandwala et al. [50] stated that total lung cancer diagnostic cost was $38.3M in a 
study sample, of which 43.1% was accounted for by biopsied patients without a lung 
cancer diagnosis. The study was conducted to assess the diagnostic costs leading up to a 
lung cancer diagnosis in patients in the timeframe from January 1, 2009 to December 31, 
2011 [50]. 
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About 234,030 new cases of lung cancer are estimated in the U.S. in 2018. Among them 
121,680 are men and 112,350 are women [51]. The estimate is from research of The 
American Cancer Society.  
 
S. Leong [52] found that in 2013, electromagnetic navigation bronchoscopy (ENB) was 
used for 3,371 bronchoscopic lung biopsy procedures and endobronchial ultrasound 
(EBUS) was used for 15,293 of these biopsy procedures. Both EBUS and ENB are 
bronchoscopic techniques to diagnose lung cancer. The overall diagnostic yield for ENB 
ranges from 59% to 77.3% [52]. M. Anastasia De Roza et al documented that the 
diagnostic yield of ENB has been recorded at only 67 to 73% [53]. Another 
bronchoscopic biopsy tool, transthoracic needle biopsies, is found to have the risk of 
pnuemothorax between 9 and 54% [54]. These scenarios, of low yield and high risk 
associated with the existing lung biopsy tools, lead to a promising peripheral lung biopsy 
tool, which is proposed here.  
 
The proposed tool of peripheral lung biopsy has the potential to reduce the risk of 
pneumothorax and improve patient comfort. It would perform bronchoscope based 
peripheral lung biopsy without the need for an ENB (electromagnetic navigation 
bronchoscopy) system. It has improved capabilities of existing ENB systems [56]. A 
SuperDimension electromagnetic navigation bronchoscopy (ENB) system costs $193,000 
[55]. 
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Figure 4:  Proposed Peripheral Lung Biopsy Tool 
 
The peripheral lung biopsy tool includes a camera chip, an EBUS (endobronchial 
ultrasound) sensor, and biopsy capabilities all in one tool. It is sized to be deployed 
through the 2mm tool port of a traditional bronchoscope. The biopsy tool is steerable. 
[56].  For estimating the target market for the proposed lung biopsy tool, primarily we 
consider that this tool would be used in 40% of the lung cancer patients. In 2011, 43.1% 
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of the lung cancer patients were accounted for lung biopsy [50], that’s why we primarily 
choose to consider 40% of the new lung cancer cases would use the proposed lung biopsy 
tool. The estimated number of new cases of lung cancer is 234, 030 in 2018 [51]. 
Therefore, the potential market size for the proposed peripheral lung biopsy tool per year 
would be approximately 93,600 (i.e. 40% of the 234,030 new cases of lung cancer). 
 
 GBM TumorID 5.3
In the U.S. there are approximately 700,000 people with a primary brain and central 
nervous system tumors. About 80,000 new cases of primary brain tumors are likely to be 
diagnosed in 2018 [58]. 
 
According to an estimate of the National Cancer Institute, 22,850 adults were diagnosed 
with brain and other nervous system cancer in 2015. Among them 12,630 were men and 
10,280 were women [59]. The study showed that two to three persons per 100,000 adults 
per year has GBM (Glioblastoma), and 52% of all primary brain tumors are GBM. 
Overall, about 17 percent of all brain tumors (including primary and metastatic) are found 
as GBM [59].  
 
The proposed tool of Glioblastoma (GBM) TumorID is a handheld device, which intends 
to measure differences in the tissues electrical impedance levels to identify tumor 
margins for optimal tumor resection. It has demonstrated proof of concept on mice with 
glioblastoma. Favorable results indicate the ability to distinguish intraoperatively 
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between tumor tissue and normal brain tissue for maximum resection of brain tumors 
with minimal damage to normal tissue [57].  
 
Opportunities for this device include ease of use and potential time savings compared to 
current methodologies. But there are some challenges including low impact on outcomes, 
low marketability and access, comparatively small market etc. Market size is estimated as 
12,760 per year [60]. The global glioblastoma multiforme (GBM) market size is 
predicted to reach USD 1.15 billion by 2024 [61]. Estimated 10-year NPV for this project 
is $8,207,000 [57].  
 
Figure 5: Preliminary CAD design of TumorID 
 
The proposed TumorID device could be considered as FDA Class II device (performance 
standard) as long as it provides only measurements that a physician interprets as part of 
making a diagnosis. In this scenario, the “measurement only” device could provide the 
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physician with an impedance measurement (or other measurement), which the physician 
could then check against published literature. 
 
 SWOT analysis of the projects 5.4
A SWOT (Strength, Weakness, Opportunity and Threat) analysis is a strategic planning 
method. It is carried out to evaluate internal strengths and weaknesses, along with its 
external opportunities and threats of an organization or a project. It helps identify the 
objective of the project, in this case, potential aspects of commercialization of medical 
device innovations.  
Based on the literature review and overview of the proposed medical devices of this 
study, a SWOT analysis was performed. It is displayed in Table 6. 
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Table 6: SWOT analysis of the proposed medical devices  
Name of the 
proposed 
medical devices 
Strength Weakness Opportunity Threat 
High-pressure 
water jet 
Craniotome 
Comparatively 
less expensive 
than the 
existing 
modified 
craniotomes, 
since it acts as 
a dura guard 
Market for 
dura guard 
may be small 
(more research 
needed) 
Technology may 
be applied to 
other 
neurosurgical 
applications 
Competition 
in target 
market 
segment 
Considerable 
number of 
potential 
licensing 
partners- Good 
Patent scope 
Potential ease 
in Technology 
transfer 
Resource 
availability 
Clear need 
from 
neurosurgeons 
160,000 
craniotomies 
performed per 
year in the 
United States. 
Peripheral lung 
biopsy 
Perform 
bronchoscope 
without the 
need for an 
ENB system 
Low potential 
venture capital 
 
Improved 
capabilities of 
existing ENB 
systems 
Increased 
adoption of 
ENB system 
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Name of the 
proposed 
medical devices 
Strength Weakness Opportunity Threat 
Glioblastoma 
TumorID 
Selective tumor 
type 
application 
High cost of 
technology 
development 
and possible 
clinical trials 
[57] 
Low technology 
complexity 
Very small 
market size- 
approximately 
12,000 per 
year 
Potential 
licensing 
hurdles 
 
 Proposed Decision Matrix for Heterogenous Technologies 5.5
Based on the SWOT analysis and discussion of the proposed tools (see Section 5.1, 5.2 
and 5.3), a decision matrix for the mentioned projects is proposed here.  
 
Scoring: Scale range for the proposed decision matrix is considered from 1 to 5. 
Potential market size range: 10,000-20,000 = score 1; 20,000-50,000= score 2; 50,000-
100,000= score 3; 100,000- 150,000= score 4; over 150,000= score 5. 
 
Technological Feasibility range: prospect of improvement of existing technology (how 
much invention needed)- 1= poor, 2= fair, 3= good, 4= very good and 5= excellent. 
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 Reimbursement Potential: 1= No code, but more expensive. 2= No code, costs the same, 
3= costs the same, there’s an existing code, 4= existing code, costs the same, effective, 5 
=existing code, more effective than existing, cheaper, better.  
 
Regulatory pathway range: 1 = significant regulatory hurdles (Class III device with a 
large human trial required for FDA clearance), 3= Moderate regulatory hurdles (Class II 
device), 5 = minimal regulatory hurdles (Class I device).  
 
Technology transferability/ Licensing range: Strategies for early stage impediments 
including intellectual property protection: 1= poor, 2= fair, 3= good, 4= very good and 5= 
excellent. 
 
Resource availability range: Based on venture capital availability and access to finance: 
1= poor, 2= fair, 3= good, 4= very good and 5= excellent. 
 
Rationale for selection of score for different decision criteria of the proposed 
medical devices 
Potential market size for high-pressure water jet craniotome, peripheral lung biopsy and 
glioblastoma tumorID are around 160,000, 93,600, and 12,000 approximately (Section 
5.1, 5.2 and 5.3). Therefore, market size for these devices are assigned as 5, 3 and 1 for 
high-pressure water jet craniotome, peripheral lung biopsy and glioblastoma tumorID 
respectively. 
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Prospect of improvement of existing technology is very good for each of the proposed 
medical devices, since they all are modifications of the existing medical device 
technologies. Hence, technology feasibility score for the three medical devices are 
assigned as 4 according to the scoring range.  
 
Both high-pressure water jet craniotome and glioblastoma tumorID have existing codes, 
which cost the same and effective as the existing code. That’s why we assigned the 
reimbursement potential score of 4 to these devices. Peripheral lung biopsy has existing 
code, which is more effective than existing, cheaper, better. Hence, according to the 
scoring range, the reimbursement potential score of 5 is proposed for peripheral lung 
biopsy. 
  
All three proposed medical device technologies mentioned here are class II device [63].  
Innovators would have to face moderate regulatory hurdles for commercializing these 
devices. The regulatory pathway score for the three devices in this study is 3.  
 
High-pressure water jet craniotome has an excellent scope of licensing with considerable 
number of potential licensing partners (see section 5.1). That’s why we assigned 
technology transferability score of 5 as per the scoring range of this study. IP scope for 
peripheral lung biopsy is less than that of the high-pressure water jet craniotome, 
technology transferability score of 4 is proposed for lung bipsy tool here. Licensing 
hurdles for glioblastoma tumorID are potentially highest (see the SWOT analysis) 
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compared to the other two medical devices discussed here and so transferability score of 
3 is proposed for the tumorID. 
 
Potential of venture capital availability for high-pressure water jet craniotome is found to 
be higher than that of the other two devices. The scope of resource availability for 
glioblastoma tumorID is found to be a little higher than peripheral lung biopsy. Weaker 
IP for the lung biopsy tool may lead to less investment, because of the complexity of the 
device. TumorID requires more testing to get to market and potentially would need to 
raise more capital. Therefore, resource availability score for high-pressure water jet 
craniotome, peripheral lung biopsy and glioblastoma tumorID are proposed as 5, 3 and 4. 
 
As per above discussion, the decision matrix for the proposed medical devices is shown 
in Table 7. The values of decision matrix itself do not provide a complete picture of 
decision criteria. In order to obtain data of relative importance of each deciding factor for 
technology commercialization, a survey is conducted. The survey results are shown in the 
next sections.  
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Table 7: Proposed decision matrix for the proposed medical devices 
Decision Criteria High-pressure 
water jet 
Craniotome 
Peripheral lung 
biopsy 
Glioblastoma 
TumorID 
Market Size 5 3 1 
Technological Feasibility 4 4 4 
Reimbursement Potential 4 5 4 
Regulatory pathway 3 3 3 
Technology transferability/ 
Licensing 
5 4 3 
Resource availability 5 3 4 
Total Score 26 22 19 
 
In the next section, the calculation is described for overall score of the proposed medical 
devices, considering the relative weights of the proposed TCFs. 
 
6 Survey Methodology: 
A survey was conducted via Qualtrics.com, an online survey tool of the University of 
Minnesota. A determination was made by the U of M that this study did not constitute 
human subjects research.  The survey intended to weight decision criteria for technology 
commercialization factors, relative to each other. Now, the survey details along with 
discussion of the result are presented below.  
 
The survey requests were sent to 42 people involved in medical device industry. 18 
people responded to the survey. Therefore, the response rate was recorded as 42.86%. 
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Screenshots of the survey questions and a sample survey response are attached in the 
‘Appendix’ section. 
 
Following are the proposed decision criteria for commercialization of medical devices: 
 Market Size - Potential market size for the projected medical device 
 Technological Feasibility- Prospect of improvement of existing technology (how 
much invention needed) 
 Reimbursement Potential- Utilizing existing reimbursement pathways for a new 
technology, rather than pursuing new coding 
 Regulatory pathway- Extent of regulatory hurdles to be faced 
 Technology transferability/ Licensing- Strategies for early stage impediments 
 Resource availability- Venture capital availability and access to finance 
 
For Question 1, participants were asked to assign weights on each of these factors in 
terms of importance as decision criteria for commercialization of medical devices on a 
scale of (1-3). 3= Most important, 2= Important, 1= Least important. 
The responses for Question 1 of the survey is shown in Table 8: 
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Table 8: Percentage of the respondents assigning the relative importance of TC 
(Summary of results for Question 1 of the survey) 
 Relative Importance 
Proposed Technology 
Commercialization Factors 
Most 
Important   
Important Least 
Important 
3 2 1 
Market size 55.6% 44.4% 0.00% 
Technological Feasibility 72.2% 27.8% 0.00% 
Reimbursement Potential 55.6% 44.4% 0.00% 
Regulatory Pathway 22.2% 72.2% 5.6% 
Technology transferability/ 
Licensing 
22.2% 55.6% 22.2% 
Resource availability 22.2% 44.5% 33.3% 
 
 
The desired proportion for the factor ‘market size’ was 55.6% as most important (=3) and 
44.4% as important (=2) (Results’ screenshots are provided in the Appendix section, 
named as Q11 for market size, Q12 for Technological feasibility and so on). 
‘Technological feasibility’ was marked as most important (=3) by 72.2% participants and 
important (=2) by 27.8% of the participants. Similarly, 55.6% participants chose the 
factor ‘Reimbursement Potential’ as most important (=3) and 44.4% as important (=2). 
‘Regulatory pathway’ was marked as important (=2) by 72.2% participants and most 
important (=3) by 22.2% of the participants and least- important (=1) by 5.6% 
participants. 
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55.6% participants chose the factor ‘Technology transferability/ Licensing’ as important 
(=2), 22.2% as important (=2), and 22.2% as least- important (=1). The desired 
proportion for the factor ‘Resource availability’ was 44.5% as important (=2), 33.3% as 
least- important (=1) and 22.2% as most important (=3) 
 
For Question 2, participants were asked if they have any recommendation to add any 
Technology Commercialization Factors (TCF) other than the mentioned ones. 55.6% of 
the participants said ‘Yes’ and they recommended their opinion as directed in Question 3. 
44.4% of the participants said ‘No’ to Question 2, which means they agree with the 
proposed with the Technology Commercialization Factors.   
 
Participants were requested to mention any recommendation to add any TCF in Question 
3. Following is the table of the response (original quote of the respondents) of the list of 
recommendation of additional Technology Commercialization Factors (TCF). 
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Table 9: List of recommendation of additional technology commercialization factors 
(TCF) 
Respondents Feedback 
1 Clinical unmet need (current solution is poor or with poor outcomes), 
competitive activity in the space, IP position, knowledge or know how of 
the people introducing the new technology. 
2 Clear path to profitability. Even if you have all the other factors, if it 
doesn't make business sense it won't be successful. Include clinical utility 
with technological feasibility. Just because you can build it doesn't mean 
anyone will want to use it. 
3 Patient impact (of the disease/condition on quality of life as well as the 
ability of the technology to remedy) Potential for cost savings to payors 
and providers Patent landscape (available whitespace and freedom to 
operate) 
4 Patent landscape & competitors in the market. 
5 Strong Intellectual Property, Strong and Diverse Team 
6 Competitive position (is there one or more competing products) 
7 Amount of capital required to get to the market? Have other technology 
startups been acquired? If yes, for how many dollars and at what stage 
i.e. post FIM, FDA approval or after demonstration of reimbursement? 
8 Team composition and expertise Freedom to operate and IP protectability 
9 Appropriate technical and business staff 
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Respondents Feedback 
10 Evidence exists to supports a claim that the device delivers better 
outcomes at a lower cost than existing solutions. 
 
The participants were requested to provide any feedback to the proposed Technology 
Commercialization Factors list. There were four feedbacks recorded for this question. 
The quoted response is listed below in Table 10: 
 
Table 10: Feedback to proposed technology commercialization factors list: 
Respondents Feedback 
1 I see you wanted to rank the top technology commercialization factors, 
however this is probably not how people would look at it, rather they 
would look at each factor on a pass/fail basis. i.e. you need to have all 
these factors as considerations and they all need to be feasible or "green 
lights". You can have "yellow lights" that you still need to develop or 
work out the strategy, but any one factor that is "red" would likely kill 
the project if it is truly a "red light". For example, if the market is too 
small, or the reimbursement is lower than cost of technology to solve it, 
or regulatory pathway is $$$ in clinical studies and years to marketability 
with a small market potential etc... none of the factors outweigh the 
others, as you need them all to at least be reasonable. 
2 More just a comment, that how I think about these issues is less of a 
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Respondents Feedback 
weighted factor and more of a threshold. E.g. is the market 100 million 
or more? Can it be built? Can you get paid for it? Can it be FDA 
approved? If yes to all then proceed. If not, then find a new project. The 
trick is that you won't get all the needed information to say Yes to each 
one at the same time, so you will need to iterate and investigate each one. 
Usually, I look to see what the market potential is first because that is 
fairly easy. If it is more than $100 million it might be worth it. Then do a 
quick assessment if the technology is feasible. Then check the regulatory 
and reimbursement pathways because those depend on the technology. 
Finally, how much will it take to get it to market. Usually, along the way 
the idea will change e.g. an idea for a different tech that is actually a 
different market, so the process will start again. 
3 In my opinion, technology transferability (potential ability to license as 
I'm understanding it) is the combined result of the other factors. 
4 The level of importance is difficult to ascribe to each of these factors, 
since any one could potentially lead to failure of commercialization 
efforts. 
 
Finally, participants were asked to mention their roles in medical device industry in 
Question 5. The result is shown below in Table 11: 
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Table 11: Roles of the respondents in medical device industries 
Roles in 
medical device 
industries 
Engineering Management Academic 
researcher 
Investor 
Percentage of 
respondents 
36.8% 29% 26.3% 7.9% 
 
Respondents chose more than one roles in medical device industries if applicable. 36.8% 
participants indicated that they are in Engineering role, whereas 29%, 26.3% and 7.9% of 
the participants mentioned that they are in Management, Academic Researcher and 
Investor roles in medical device industries.  
 
7 Discussion of Results 
 Data Analysis 7.1
This section presents all data analysis and calculation of the relative weightings of the 
proposed technology commercialization factors (TCF). At first, the assigned relative 
importance to the TCFs from the response of the survey is tabulated and analyzed. The 
distribution of the relative importance is also analyzed for statistical analysis later. The 
calculation for weighted scoring is also demonstrated in this data analysis section.  
 
Based on the survey result, relative weighting of the proposed technology 
commercialization factors (TCF) is calculated. For ease of calculation, the percentage 
values (of Table 8) are converted into decimal values here. For example, 55.6% is 
converted to 0.556 (in Table 12). The calculation is shown below in Table 12: 
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Table 12: Relative weighting of the proposed technology commercialization factors  
 Relative Importance  
Proposed Technology 
Commercialization 
Factors 
Most 
Important   
Important Least 
Important 
Weighted 
score of 
Proposed TC 
Factors 
3 2 1 
Market size  0.556 0.444 0 2.556 
Technological 
Feasibility 
0.722 0.278 0 
2.722 
Reimbursement 
Potential 
0.556 0.444 0 
2.556 
Regulatory Pathway 0.222 0.722 0.056 2.166 
Technology 
transferability/ 
Licensing 
0.222 0.556 0.222 
2.00 
Resource availability 0.222 0.445 0.333 1.889 
 
Figure 6 outlines the calculation of relative weighting of the proposed TC factors.  
The statistical importance of the TC factors is discussed in the ‘Statistical analysis’ 
section to identify the statistical significance between the weightings. 
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Figure 6: Calculation of relative weighting of the proposed technology commercialization 
factors 
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Key formula for weighted score of an individual TC factor is SUMPRODUCT of the 
Percentage of response (from the survey) for that factor and Relative importance value. 
For example, Technological feasibility was marked as most important (=3) by 72.2% 
participants and important (=2) by 27.8% of the participants. So, the weighted score for 
Technological feasibility is (0.722*3+0.278*2+0*1) = 2.722. 
 
Following is the depiction of distribution of relative importance of the TC factors in a bar 
chart: 
 
Figure 7: Distribution of relative importance of TC factors 
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X-axis and Y-axis stand for the relative importance of the factors and the number of 
participants assigning that relative importance on each TC factor respectively.  
Now, calculated values of the proposed TC factors weights from Table 12 are applied to 
the proposed medical devices of this study. Here, data from decision matrix (See Section 
5.5) is used as well. Table 13 below shows the detailed results: 
 
Table 13: Calculation of overall score of proposed technology commercialization factors 
of proposed medical devices 
  Proposed Medical Devices 
Proposed 
Technology 
Commercialization 
Factors 
Weighted 
score of 
Proposed 
TC Factors 
High-pressure 
water 
jet Craniotome 
Peripheral 
lung 
biopsy 
Glioblastoma 
TumorID 
Technological 
Feasibility 
2.722 4 4 4 
Market size  2.556 5 3 1 
Reimbursement 
Potential 
2.556 4 5 4 
Regulatory Pathway 2.166 3 3 3 
Technology 
transferability/ 
Licensing 
2 5 4 3 
Resource availability 1.889 5 3 4 
 Overall 
Score 
59.835 51.501 43.722 
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Figure 8 outlines the calculation for overall score of proposed technology 
commercialization factors of the proposed medical devices.  
 
 
Figure 8: Calculation of overall score of proposed technology commercialization factors 
of proposed medical devices 
 
Key formula for overall score of an individual medical device is SUMPRODUCT of the 
calculated weighted score of the proposed TC factor for that medical device and Decision 
Matrix Score of that device taken from Table 7. For example, overall score for High-
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pressure water jet Craniotome is: (2.556*5+ 2.722*4+2.556*4+ 2.166*3+2*5+1.889*5) 
= 59.835. Hence, overall scores of the proposed technology commercialization factors of 
proposed medical devices in Table 14: 
 
Table 14: Overall scores of the proposed TCF of proposed medical devices 
Proposed medical 
devices 
High-pressure water 
jet craniotome 
Peripheral lung 
biopsy 
Glioblastoma TumorID 
Overall TCF 
score 
59.835 51.501 43.722 
 
The high-pressure water jet craniotome, having highest overall score among the three 
medical device innovations, shows most promising aspect to commercialize, considering 
the proposed technology commercialization (TC) factors here. The statistical significance 
of relative weightings of TC factors is described in the next section. 
 
 Statistical analysis 7.2
Table 12 and Figure 6 showed the calculation of the weights for the proposed TC 
Factors. Now, to determine if there is a statistical difference between the weightings, a 
statistical analysis is represented here.  
Following is the table of the outline of the statistical analysis: 
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Table 15: Outline of the statistical analysis 
Statistical analysis tool Minitab 
Sample size  18 
Analysis method one-way ANOVA analysis (Welch’s method) 
Obtained p-value  <0.001 (robust evidence against the null 
hypothesis when p ≤ 0.05) (See Figure 9) 
Summary of result There is a statistical difference between the 
mean ranking of the TCF values 
 
The participants of the survey assigned relative importance to each proposed TC factor. 
There were 18 participants who responded to the survey questions related to weighting 
the TC factors. Table 16 below shows the survey data used for the identification of 
statistical significance of the TC factors. The screenshot this data utilized in Minitab is 
included in the ‘Appendix’ section as well. For a graphical portrayal of break-down of 
the assigned relative importance to each factor, see Figure 7.  
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Table 16: Survey data for statistical analysis 
 
 Importance of the individual TC factor assigned by the participants  
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1 3 3 2 2 2 2 
2 3 3 2 2 3 2 
3 3 3 3 3 2 3 
4 3 2 2 2 1 2 
5 2 3 3 3 2 3 
6 2 3 3 2 2 1 
7 3 3 2 3 2 2 
8 3 3 2 2 2 1 
9 2 3 2 2 2 3 
10 2 3 2 3 1 1 
11 2 2 3 2 2 1 
12 2 3 2 2 3 3 
13 2 2 3 2 3 1 
14 2 2 3 2 1 1 
15 3 2 3 1 1 2 
16 3 3 3 2 2 2 
17 3 3 3 2 2 2 
18 3 3 3 2 3 2 
 
Figures 9, 10, 11 and 12 show one-way ANOVA (Analysis of Variance) analysis 
Summary Report, Diagnostic report, Power report and Report card respectively. 
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Figure 9: One-way ANOVA analysis Summary Report 
 
A Summary Report of one-way ANOVA analysis of the survey response, which was 
carried out in Minitab, is shown on Figure 9. A null hypothesis is a hypothesis that 
intends to prove that there is no statistical significance between the variables in the given 
hypothesis. The researcher tries to invalidate the null hypothesis [64]. 
 
The alternative hypothesis is the one the researcher would believe if the null hypothesis is 
concluded to be untrue. All hypothesis tests ultimately use a p-value to weigh the strength 
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of the evidence. A p-value helps determine the significance of the results.  A p-value of ≤ 
0.01 indicates very strong indication against null hypothesis. A p-value of ≤ 0.05 
indicates convincing evidence against the null hypothesis, so the null hypothesis is 
rejected. A large p-value (> 0.05) indicates weak evidence against the null hypothesis, 
then it fails to reject the null hypothesis [65]. The relationship between p-value and 
conclusive result of null hypothesis is summarized in Table 17: 
 
Table 17: Relationship between p-value and conclusive result of null hypothesis 
p-value Decision on Null hypothesis 
p≤ 0.01 very strong evidence against null hypothesis: Reject null hypothesis 
p≤ 0.05 strong presumption against null hypothesis: Reject null hypothesis 
p> 0.05 weak evidence against the null hypothesis: Failure to reject null 
hypothesis 
 
Here in this study, the null hypothesis was to prove that that there is no statistical 
significance between the TC factors. The p-value is then calculated as <0.001 from 
Minitab one-way ANOVA analysis, which is less than 0.05. Therefore, the null 
hypothesis is rejected since differences among the means are significant, and so, there is a 
statistical difference between the mean raking of the TC factor values. In other words, 
there are differences among the means at the 0.05 level of significance.  
From the ‘Means comparison chart’ of the summary report, the red intervals do not 
overlap, which identifies that the means differ from each other.  
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Figure 10: One-way ANOVA analysis Diagnostic Report 
 
Diagnostic Report helps to explore the chance of detecting a significant difference. The 
power report of one-way ANOVA analysis shows this result in detail. Here, distribution 
of data for TC factors is shown in the diagnostic report.  
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Figure 11: One-way ANOVA analysis Power Report 
 
Power is a function of sample sizes and standard deviations. Based on the Power report 
and Report card, it is proven that that the sample size was sufficient to detect the 
difference among the means with high confidence.  
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Figure 12: One-way ANOVA analysis Report card 
 
 Discussion 7.3
The list of recommendation of additional Technology Commercialization Factors 
enlightens few new TCFs to be considered. For example, team composition could be a 
possible commercialization factor to add, since there were recommendations as ‘Strong 
and Diverse Team’, ‘Team composition’, ‘Appropriate technical and business staff’.  
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The factor ‘Team Composition’ relates to the size and the background of the teams 
working on projects which ultimately impacts technology commercialization process. 
Here, the background refers to previous experience, whether it might be entrepreneurial 
skill or industrial exposure. Technology focus and proper marketing skills also play 
significant role in building the background of the teams. 
 
The composition of startup founding teams has been studied in different business 
environments. Eesley et al. [66] suggested that the founding teams should be diverse in 
competitive commercialization spheres. When followed by an innovation strategy in a 
cooperative environment, technically focused teams perform better [66]. 
 
Per Roure and Keeley [67], the success of an innovative commercialization depends on a 
complete founding team. Cross-functional collaborations of the team helps improving TC 
performance. In addition, Eisenhardt and Schoonhoven [68] proposed that the success of 
a new company may contingent on prior experience of the appropriate technical and 
business staff. Team members with diverse industry experience positively affect growth 
rates of the startup companies [67] [68].  
 
Diversity in team members introduces a knowledge-creating entity, which would benefit 
the build-up process of new companies. To commercialize a new product or service, 
starting from university-based research, the involvement of the university researchers is 
crucial.  Per Jensen and Thursby [69] the academic staff, who developed the new 
technology, needs to be involved in the further development of the new technologies 
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towards a successful commercialization. According to O’Shea et al and Powers and 
McDougall [70] [71], higher rates of spin-off success are accompanied with faculty leads 
with integrity and technical aspects. Ambos et al. [72] suggested that a higher 
involvement in TC activities has also led to more spin-offs. 
 
O’Shea et al. [68] also emphasized the quality of the academic staff over the quantity for 
the spinning-off of companies. Rasmussen and Borch [73] recommended that university 
spin-offs be highly associated with students and academics, who have good industrial 
exposure and entrepreneurial interest. Especially appropriate are academic staff who 
would substantially support the technology commercialization with their market-insights 
and target market forecasts based on the customers’ point of views [73]. Therefore, 
proper team composition with well-organized and diverse team-members can lead to 
successful spin-offs and commercialization. 
 
Another recommended TCF, which can be mentioned here, was Intellectual Property/ 
Patent landscape. Respondents used the terms as ‘IP position’, ‘Freedom to operate’, 
‘Patent landscape’, ‘Strong Intellectual Property’, ‘IP protectability’. But, the proposed 
TCF list enlisted the factor of ‘Technology transferability/ Licensing’ which encompasses 
intellectual property/ patentability and freedom to operate. It is possible that the initial 
information presented in the survey questions provided a very brief information about 
what the factors really stood for. However, from the feedback of the participants of the 
survey, patent landscape is noted to be an important factor for technology 
commercialization. 
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 Limitation of the study and future work 7.4
The survey results might have been different if the number of the participants would be 
even larger as the variation in the result could have been smaller or larger in that case. It 
is recommended that the addition of other technology commercialization factors to the 
proposed factors in this paper could result in new weighted scoring for those additional 
factors. The future work includes performing the survey in longer timeframe to get 
responses from more participants. 
 
The future work also includes the implementation of the research methodology of this 
study in case of deciding a new technology to commercialize. The methodology of this 
study shows quantified result which proves that the decision-making approach, for 
choosing one technology over another, works. Therefore, a pilot project is recommended 
to show the application of the research methodology of this study. The result of the pilot 
project will bolster the validity of the decision made by the proposed approach to achieve 
successful commercialization. 
 
8 Conclusion 
This study provided a comprehensive picture of decision criteria for technology 
commercialization factors (TCF) of three heterogeneous medical devices: high pressure 
water jet craniotome, peripheral lung biopsy, and glioblastoma TumorID. After analyzing 
the SWOT analysis and literature review, initial scores were assigned to the proposed 
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technology commercialization factors from a decision matrix. A survey was held to 
weight the decision criteria for technology commercialization. It was recorded that 
participants assigned the most importance on Technological Feasibility (weighted score 
of 2.722). The second most important factors were found as Market Size and 
Reimbursement Potential (weighted score of 2.556). Statistical analysis of the TC factors 
proved that the there is a significant statistical difference between the mean raking of the 
TC factor values. 
 
Additional TCF, recommended as Team Composition and Patent Landscape, were 
reflected from the feedback. Therefore, further research with these additional TCFs is 
highly recommended for future study. Since, the weighted scores were only recorded 
from the current proposed TCF list, the overall score for decision criteria for the 
technology commercialization factors (TCF) of the three medical devices have been 
calculated accordingly. Finally, high pressure water jet craniotome shows most promising 
aspect for technology commercialization based on this study. The overall score for the 
technology commercialization of the peripheral lung biopsy tool was recorded as 51.501, 
whereas high pressure water jet craniotome scored 59.835 and glioblastoma TumorID 
scored 43.722. Therefore, weighting of TC factors helps decision-making for the 
innovator/startup firm, or in this case, university technology transfer efforts.  
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Appendix: Survey Questionnaire  
 
 
Figure 1: Survey Questionnaire, page 1 
 
 
Figure 2: Survey Questionnaire, page 2 
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Figure 3: Survey Question 01- Choices 1 and 2 
 
 
Figure 4: Survey Question 01- Choices 3 and 4 
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Figure 5: Survey Question 01- Choices 5 and 6 
 
 
Figure 6: Survey Question 02- Response count 
 
 
Figure 7: Survey Question 03- Responses 
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Figure 8: Survey Question 04- Responses 
 
 
Figure 9: Survey Question 05- Response count 
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Figure 10: Sample response of the Survey 
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Figure 11: Minitab screenshot of the statistical data for ANOVA one-way analysis 
 
